



22 March 2017

By Courier, Fax and Email

1. The BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400 001
Tel No.: +91 22 2272 1233/ 4
Fax No: +91 22 2272 3121
Email: corp.relations@bseindia.com

2. National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051
Tel No: (022) 26598100 - 8114
Fax No: (022) 26598120
Email: takeover@nse.co.in

GlaxoSmithKline Pte Ltd
150 Beach Road,
#22-00 Gateway West,
Singapore 189720

T +65 6232 8338
F +65 6392 5972
www.gsk.com

Dear Sirs,

Re: Disclosures under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

This is to inform you that we, GlaxoSmithKline Pte Ltd, having our registered office at 150 Beach Road, #21-00, Gateway West, Singapore 189720, are addressing this letter to you for the purpose of disclosing the proposed acquisition of 31,92,238 equity shares held by Castleton Investment Ltd., Mauritius in GlaxoSmithKline Pharmaceuticals Limited which is listed on the BSE Limited and the National Stock Exchange of India Limited. We are enclosing herewith the Form for disclosure of details of the proposed acquisition of equity shares in terms of Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Please note that we had inadvertently filed/ submitted a disclosure yesterday (i.e. 21 March 2017) with a proposed date of acquisition of the equity shares as being 28 March 2017 (which we now understand is a public holiday). Hence we are resubmitting this disclosure with the revised date as being 30 March 2017 as the proposed date of acquisition.

Yours faithfully,

For GlaxoSmithKline Pte Ltd


Authorised Signatory
(Jason Nicholas Masi, Director)

Encl: a/a


Format for Disclosures under Regulation 10(5) – Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited
2.	Name of the acquirer (s)	GlaxoSmithKline Pte Ltd
3.	Whether the acquirer(s) is/ are promoters of the TC prior to the transaction. If not, nature of relationship or association with the TC or its promoters.	The acquirer forms part of the promoter and promoter group
4.	Details of the proposed acquisition	
	a. Name of the person(s) from whom shares are to be acquired	Castleton Investment Ltd
	b. Proposed date of acquisition	30 March 2017
	c. Number of shares to be acquired from each person mentioned in 4(a) above	31,92,238
	d. Total shares to be acquired as % of share capital of TC	3.77%
	e. Price at which shares are proposed to be acquired	Approximately INR 2740 Note: Since the parties have agreed that the price would be determined on the basis of the closing price of the shares 2 working days before transfer, the above price has been determined on the basis of the closing price of shares on the previous trading day prior to the date of this filing (i.e. 21 March 2017) and hence the final/ actual price could be subject to minor changes.
	f. Rationale, if any, for the proposed transfer	Inter-se transfer between promoter & promoter group
5.	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer.	Regulation 10(1)(a)(iii)
6.	If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.	2711.7
7.	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	N.A.

8.	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.	The acquisition price is not higher by more than 25% of the price computed in point 6 above.			
9.	i. Declaration by the acquirer, that the transferor and transferee have complied (during 3 years prior to the date of proposed acquisition)/will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997) ii. The aforesaid disclosures made during previous 3 years prior to the date of proposed acquisition to be furnished.	i. The acquirer hereby confirms that the transferor and the transferee have complied (during 3 years prior to the date of proposed acquisition) and will comply, with the applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011. ii. Please see enclosed the copies of the disclosures made by the transferor and the transferee during the previous 3 years prior to the date of the proposed acquisition, in terms of Chapter V of the Takeover Regulations, 2011.			
10.	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.	The acquirer hereby confirms that all the conditions specified under regulation 10(1)(a) of the Takeover Regulations, 2011 with respect to exemptions have been duly complied with.			
11.	Shareholding details	Before the proposed transaction		After the proposed transaction	
		No. of shares/ voting rights	% w.r.t total share capital of TC	No. of shares/ voting rights	% w.r.t total share capital of TC
	a. Acquirer(s) and PACs (other than sellers) (*) (i) Glaxo Group Ltd. (ii) GlaxoSmithKline Pte Ltd (Acquirer) (iii) Eskaylab Ltd. (iv) Burroughs Welcome International Ltd. Total of (a):	3,04,85,250 2,06,09,774 58,80,000 33,60,000 6,03,35,024	35.99% 24.33% 6.94% 3.97% 71.23%	3,04,85,250 2,38,02,012 58,80,000 33,60,000 6,35,27,262	35.99% 28.10% 6.94% 3.97% 75%
	b. Seller (s) Castleton Investment Ltd	31,92,238	3.77%	NIL	NIL

Note:

- (*) Shareholding of each entity may be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.



Authorised Signatory
(Jason Nicholas Masi, Director)
GlaxoSmithKline Pte Ltd
22 March 2017
Singapore

CIL- Jom-2014 - to Company

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited			
2. Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange: BSE National Stock Exchange: NSE			
3. Particulars of the shareholder(s): a) Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name(s) of promoter(s), member of the promoter group and PAC with him.	Glaxo Group Limited GlaxoSmithKline Pte Limited Eskaylab Limited Burroughs Wellcome International Limited Castleton Investment Limited			
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total share/voting of TC (*)	Diluted capital
As of March 31st of the year, holding of:				
a) Shares	63527262	75%	75%	84703017
b) Voting Rights (wherever applicable)				
c) Warrants,	-	-	-	-
d) Convertible Securities	-	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-	-
Total				

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Signature of the Authorized Signatory:



Paul Williamson
Authorized Signatory
For and on behalf of
The Wellcome Foundation Limited
Corporate Director

Date: 1st April 2014

Place: England

NSE



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

4th April 2014

NATIONAL STOCK EXCHANGE,
EXCHANGE PLAZA, 5TH FLOOR,
PLOT No. C/1, G BLOCK,
BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI
400051

Dear Sir,


SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith a consolidated confirmation for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleon Investment Limited in respect of their shareholding in our Company as on 31st March 2014.

We hope the same is in order.

Thanking you,

 Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited


Ajay Nadkarni
General Manager - Administration
& Company Secretary

Encl:

Corporate Identity Number
L24230MH1924PLC001161
Email Id: gskus@gsk.com
Web site address: www.gsk-india.com

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited			
2. Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange: BSE National Stock Exchange: NSE			
3. Particulars of the shareholder(s) : a) Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name(s) of promoter(s), member of the promoter group and PAC with him.	Glaxo Group Limited GlaxoSmithKline Pte Limited Eskaylab Limited Burroughs Wellcome International Limited Castleton Investment Limited			
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total share/voting of TC (*)	Diluted capital
As of March 31st of the year, holding of:				
a) Shares	63527262	75%	75%	84703017
b) Voting Rights (otherwise than by shares)	63527262	75%	75%	84703017
c) Warrants,	-	-	-	-
d) Convertible Securities	-	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-	-
Total				

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Signature of the Authorized Signatory:



Paul Williamson
Authorized Signatory
For and on behalf of
The Wellcome Foundation Limited
Corporate Director

Date: 1st April 2014

Place: England

CIL 30. 1. 2014. To NSE



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

4th April 2014

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

BOMBAY STOCK EXCHANGE LIMITED
PHIROZE JEEJEEBHAY TOWERS
DALAL STREET
MUMBAI
400001

Dear Sir,

SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith a consolidated confirmation for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleton Investment Limited in respect of their shareholding in our Company as on 31st March 2014.

We hope the same is in order.

Thanking you,

(Signature) Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

(Signature)

Ajay Nadkarni
General Manager – Administration
& Company Secretary

Encl:

Corporate Identity Number
L24239MH1924PLC001161

Email Id: askus@gsk.com
Web site address: www.gsk-india.com

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited			
2. Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange: BSE National Stock Exchange: NSE			
3. Particulars of the shareholder(s) : a) Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name(s) of promoter(s), member of the promoter group and PAC with him.	Glaxo Group Limited GlaxoSmithKline Pte Limited Eskaylab Limited Burroughs Wellcome International Limited Castleton Investment Limited			
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total share/voting of TC (*)	Diluted capital
As of March 31st of the year, holding of:				
a) Shares	63527262	75%	75%	84703017
b) Voting Rights (otherwise than by shares)	63527262	75%	75%	84703017
c) Warrants,	-	-	-	-
d) Convertible Securities	-	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-	-
Total				

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Signature of the Authorized Signatory:



Paul Williamson
Authorized Signatory
For and on behalf of
The Wellcome Foundation Limited
Corporate Director
Date: 1st April 2014

Place: England

21.6.2015- 13 company



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) :			
	a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
	or			
	b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton investment Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
	As of March 31st of the year, holding of:			
	a) Shares	3192238	3.77	3.77
	b) Voting Rights (otherwise than by shares)	-	-	-
	c) Warrants,	-	-	-
	d) Convertible Securities	-	-	-
	d) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
	Total	3192238	3.77	3.77



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	-

Signature of the Authorised Signatory

Place: Ebene, Mauritius

Date: 31 March 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

6th April 2015

NATIONAL STOCK EXCHANGE,
EXCHANGE PLAZA, 5TH FLOOR,
PLOT No. C/1, G BLOCK,
BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI
400051

Dear Sir,

SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleon Investment Limited in respect of their shareholding in our Company as on 31st March 2015.

We hope the same is in order.

Thanking you,

Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
General Manager – Administration
& Company Secretary

Encl:

Corporate Identity Number
L24239MH1924PLC001151

Email id: askus@gsk.com
Web site address: www.gsk-india.com

SEBI भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) : Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
a) Shares		3192238	3.77	3.77
b) Voting Rights (otherwise than by shares)		-	-	-
c) Warrants,		-	-	-
d) Convertible Securities		-	-	-
d) Any other instrument that would entitle the holder to receive shares in the TC.		-	-	-
Total		3192238	3.77	3.77



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	-

Signature of the Authorised Signatory

Place: Ebene, Mauritius

Date: 31 March 2015

Note:


1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India



ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) :			
	a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
	or			
	b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
	As of March 31st of the year, holding of:			
	a) Shares	20609774	24.33	24.33
	b) Voting Rights (otherwise than by shares)	-	-	-
	c) Warrants,	-	-	-
	d) Convertible Securities	-	-	-
	d) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
	Total	20609774	24.33	24.33



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	-

Signature of the Authorised Signatory

Place:

Singapore

Date:

1 April 2015

Note:

- 1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

6th April 2015

BOMBAY STOCK EXCHANGE LIMITED
PHIROZE JEEJEEBHAY TOWERS
DALAL STREET
MUMBAI
400001

Dear Sir,

SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleton Investment Limited in respect of their shareholding in our Company as on 31st March 2015.

We hope the same is in order.

Thanking you,

Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
General Manager – Administration
& Company Secretary.

Encl:

Corporate Identity Number
L24239MH1924PLC001151

Email Id: askus@gsk.com
Web site address: www.gsk-india.com

SEBI भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange ; BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) :			
	a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
	or			
	b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
	As of March 31st of the year, holding of:			
	a) Shares	3192238	3.77	3.77
	b) Voting Rights (otherwise than by shares)	-	-	-
	c) Warrants,	-	-	-
	d) Convertible Securities	-	-	-
	d) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
	Total	3192238	3.77	3.77



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	-

Signature of the Authorised Signatory

Place: Ebene, Mauritius

Date: 31 March 2015

Note:


1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India



ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) : Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
a) Shares		20609774	24.33	24.33
b) Voting Rights (otherwise than by shares)		-	-	-
c) Warrants,		-	-	-
d) Convertible Securities		-	-	-
d) Any other instrument that would entitle the holder to receive shares in the TC.		-	-	-
Total		20609774	24.33	24.33



भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	-

Signature of the Authorised Signatory

Place:

Singapore

Date:

1 April 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

CIL - 2016 - 15 Company

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	3,192,238	3.77	3.77
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	3,192,238	3.77	3.77



Name of the Target Company:



Signature of the Authorised Signatory

Place: Mauritius

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Rohan Mota

From: Ajay Nadkarni
Sent: Monday, April 04, 2016 5:24 PM
To: Rohan Mota
Subject: FW: Promoters Disclosure required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

From: Paul Williamson
Sent: Monday, April 04, 2016 5:17 PM
To: takeover@nse.co.in
Cc: Ajay Nadkarni; Amita Patel
Subject: Promoters Disclosure required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

Dear Sir,

Please find attached Promoters Disclosure(details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

Sr no	Particulars	No of Shares	Percentage
1	Glaxo Group Limited	3,04,85,250	35.99
2	Eskaylab Limited	58,80,000	6.94
3	Burroghs Wellcome International Limited	33,60,000	3.97
4	GlaxoSmithKline Pte Ltd.	2,06,09,774	24.33
5	Castleton Investment Limited	31,92,238	3.77
Total		6,35,27,262	75.00

Kindly take on record and confirm the same.

Regards
 Paul Williamson
 Corporate Secretariat

JK
 930 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
 Email paul.y.williamson@gsk.com
 Tel +442080474504

gsk.com | [Twitter](#) | [YouTube](#) | [Facebook](#) | [Flickr](#)




do more
 feel better
 live longer

This message is not intended for general use and may contain information which is sensitive, confidential or restricted. If you are not the authorised recipient, you are hereby notified that any use, copying, or distribution of this message, its contents or attachments is strictly prohibited

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s):			
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or			
b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	2,06,09,774	24.33	24.33
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	2,06,09,774	24.33	24.33



Signature of the Authorised Signatory

Place:

Date: 1st April, 2016.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	3,192,238	3.77	3.77
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	3,192,238	3.77	3.77

Name of the Target Company:



Signature of the Authorised Signatory

Place: Mauritius

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

2016

Rohan Mota

From: Ajay Nadkarni
Sent: Monday, April 04, 2016 2:02 PM
To: Anand Joshi; Rohan Mota
Subject: FW: Promoters Disclosure(details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithkline Pharmaceuticals Limited
Attachments: AADisclosures under Reg 30(1) 30(2) of SEBI Reg 2011 (2).pdf

FYI and file. Please confirm with BSE they have received this email.

Regards

Ajay

From: Paul Williamson
Sent: Friday, April 01, 2016 6:41 PM
To: corp.relations@bseindia.com
Cc: Ajay Nadkarni; Amita Patel
Subject: Promoters Disclosure(details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithkline Pharmaceuticals Limited

Dear Sir,

Please find attached **Promoters Disclosure**(details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithkline Pharmaceuticals Limited

Sr no	Particulars	No of Shares	Percentage
1	Glaxo Group Limited	3,04,85,250	35.99
2	Eskaylab Limited	58,80,000	6.94
3	Burroughs Wellcome International Limited	33,60,000	3.97
4	GlaxoSmithKline Pte Ltd	2,06,09,774	24.33
5	Castleton Investment Limited	31,92,238	3.77
Total		6,35,27,262	75.00

Kindly take on record and confirm the same.

Regards

Paul Williamson

Assistant Company Secretary – Group Operations
 Corporate Secretariat

GSK

980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom

Email paul.y.williamson@gsk.com


Tel +442080474504

gsk.com | [Twitter](#) | [YouTube](#) | [Facebook](#) | [Flickr](#)

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	2,06,09,774	24.33	24.33
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	2,06,09,774	24.33	24.33



Signature of the Authorised Signatory

Place:

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	3,192,238	3.77	3.77
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	3,192,238	3.77	3.77



Signature of the Authorised Signatory

Place: Mauritius

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Ple: Joint - 2014 - to Company

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited			
2. Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange: BSE National Stock Exchange: NSE			
3. Particulars of the shareholder(s) : a) Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name(s) of promoter(s), member of the promoter group and PAC with him.	Glaxo Group Limited GlaxoSmithKline Pte Limited Eskaylab Limited Burroughs Wellcome International Limited Castleton Investment Limited			
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total share/voting of TC (*)	Diluted capital
As of March 31st of the year, holding of:				
a) Shares	63527262	75%	75%	84703017
b) Voting Rights (otherwise than by shares)	63527262	75%	75%	84703017
c) Warrants,	-	-	-	-
d) Convertible Securities	-	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-	-
Total				

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Signature of the Authorized Signatory:



Paul Williamson
Authorized Signatory
For and on behalf of
The Wellcome Foundation Limited
Corporate Director
Date: 1st April 2014

Place: England

Pre-Joint - 2014 - to BSE



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

4th April 2014

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

BOMBAY STOCK EXCHANGE LIMITED
PHIROZE JEEJEEBHAY TOWERS
DALAL STREET
MUMBAI
400004

Dear Sir,

SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith a consolidated confirmation for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleon Investment Limited in respect of their shareholding in our Company as on 31st March 2014.

We hope the same is in order.

Thanking you,

Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni

Ajay Nadkarni
General Manager - Administration
& Company Secretary

Encl:

Corporate Identity Number
L24239MH1924PLC001181

Email Id: askus@gsk.com
Web site address: www.gsk-india.com

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited			
2. Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange: BSE National Stock Exchange: NSE			
3. Particulars of the shareholder(s) : a) Name of person(s) together with Persons Acting In Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name(s) of promoter(s), member of the promoter group and PAC with him.	Glaxo Group Limited GlaxoSmithKline Pte Limited Eskaylab Limited Burroughs Wellcome International Limited Castleton Investment Limited			
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total share/voting of TC (*)	Diluted capital
As of March 31st of the year, holding of:				
a) Shares	63527262	75%	75%	84703017
b) Voting Rights (otherwise than by shares)	63527262	75%	75%	84703017
c) Warrants,	-	-	-	-
d) Convertible Securities	-	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-	-
Total				

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Signature of the Authorized Signatory:



Paul Williamson
Authorized Signatory
For and on behalf of
The Wellcome Foundation Limited
Corporate Director
Date: 1st April 2014

Place: England

NSE.

Pte Jomr - 2014 - 10 NSE



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

4th April 2014

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

NATIONAL STOCK EXCHANGE,
EXCHANGE PLAZA, 5TH FLOOR,
PLOT No. C/1, G BLOCK,
BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI
400051

Dear Sir,


SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith a consolidated confirmation for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleton Investment Limited in respect of their shareholding in our Company as on 31st March 2014.

We hope the same is in order.

Thanking you,

 Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited


Ajay Nadkarni
General Manager - Administration
& Company Secretary

Encl:

Corporate Identity Number
L24230MH1924PLC001161
Email id: gskindia@gsk.com
Web site address: www.gsk-india.com

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited			
2. Name(s) of the stock exchange(s) where the shares of the TC are listed:	Bombay Stock Exchange: BSE National Stock Exchange: NSE			
3. Particulars of the shareholder(s): a) Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name(s) of promoter(s), member of the promoter group and PAC with him.	Glaxo Group Limited GlaxoSmithKline Pte Limited Eskaylab Limited Burroughs Wellcome International Limited Castleton Investment Limited			
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total share/voting of TC (*)	Diluted capital
As of March 31st of the year, holding of:				
a) Shares	63527262	75%	75%	84703017
b) Voting Rights (otherwise than by shares)	63527262	75%	75%	84703017
c) Warrants,	-	-	-	-
d) Convertible Securities	-	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-	-
Total				

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Signature of the Authorized Signatory:



Paul Williamson
Authorized Signatory
For and on behalf of
The Wellcome Foundation Limited
Corporate Director
Date: 1st April 2014

Place: England



GlaxoSmithKline

GlaxoSmithKline Pte Ltd
150 Beach Road
#22-00 Gateway West
Singapore 189720

Tel. +65 6232 8338
www.gsk.com

Filing under SEBI Takeover Regulations

12 March 2014

To,

✓ GlaxoSmithKline
Pharmaceuticals Limited

The Managing Director
BSE Limited
PJ Towers
Mumbai-400 001

The Managing Director
National Stock Exchange of India
Limited
Exchange Plaza
Plot No. C/1, G Block
Bandra Kurla Complex
Bandra (East)
Mumbai 400 051

Dear Sir / Madam

Sub: Filing of report under Regulation 29(1) of the SEBI Takeover Regulations.

In compliance with Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI Takeover Regulations"), we are hereby notifying the information regarding our acquisition of 20,609,774 equity shares of GlaxoSmithKline Pharmaceuticals Limited, on 10 March 2014. As required under Regulation 29(3) of the SEBI Takeover Regulations, we are informing you about the said acquisition within 2 working days of the acquisition of share in the Company.

Enclosed is the report in the format as prescribed by Securities and Exchange Board of India.

The above is for your information and records.

Thanking You,

Yours faithfully

For GlaxoSmithKline Pte Ltd,

Authorized signatory



GlaxoSmithKline

GlaxoSmithKline Pte Ltd
150 Beach Road
#22-00 Gateway West
Singapore 189720

Tel. +65 6232 8338
www.gsk.com

Disclosures under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2.	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer.	Acquirer – GlaxoSmithKline Pte Ltd PAC 1 – GlaxoSmithKline plc PAC 2 – Glaxo Group Limited		
3.	Whether the acquirer belongs to Promoter/Promoter group	Yes		
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited BSE Limited		
5.	Details of the acquisition of shares/voting rights/holding of the Acquirer and the PAC	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC (*)
	<u>Before the acquisition under consideration, holding of:</u>			
	(a) Shares carrying voting rights	Acquirer -Nil PAC 1- Nil PAC 2- 30,485,250 Other Promoter Entities – 12,432,238	Acquirer- Nil PAC 1- Nil PAC 2- 35.99% Other Promoter Entities – 14.68%	Acquirer- Nil PAC 1- Nil PAC 2- 35.99% Other Promoter Entities – 14.68%

	(b) Voting rights (VR) otherwise than by equity shares	Acquirer - Nil PAC 1- Nil PAC 2- Nil	Acquirer - Nil PAC 1- Nil PAC 2- Nil	Acquirer - Nil PAC 1- Nil PAC 2- Nil
	(c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Acquirer - Nil PAC 1- Nil PAC 2- Nil	Acquirer - Nil PAC 1- Nil PAC 2- Nil	Acquirer - Nil PAC 1- Nil PAC 2- Nil
	Total (a + b + c)	Acquirer - Nil PAC 1- Nil PAC 2- 30,485,250 Other Promoter Entities -- 12,432,238	Acquirer- Nil PAC 1- Nil PAC 2- 35.99% Other Promoter Entities -- 14.68%	Acquirer- Nil PAC 1- Nil PAC 2- 35.99% Other Promoter Entities -- 14.68%
	<u>Details of acquisition</u>			
	(a) Shares carrying voting rights acquired	Acquirer - 20,609,774	Acquirer- 24.33%	Acquirer- 24.33%
	(b) VRs acquired otherwise than by equity shares	Nil	Nil	Nil
	(c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil

	Total (a + b + c)	Acquirer – 20,609,774	Acquirer- 24.33%	Acquirer- 24.33%
	<u>After the acquisition, holding of:</u>			
	(a) Shares carrying voting rights	Acquirer – 20,609,774 PAC 1- Nil PAC 2- 30,485,250 Other Promoter Entities – 12,432,238	Acquirer – 24.33% PAC 1- Nil PAC 2- 35.99% Other Promoter Entities – 14.68%	Acquirer – 24.33% PAC 1- Nil PAC 2- 35.99% Other Promoter Entities – 14.68%
	(b) VRs otherwise than by equity shares	Nil	Nil	Nil
	(c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
	Total (a + b + c)	63,527,262	75%	75%
6.	Mode of acquisition (e.g. open market/public issue/rights issue/preferential allotment/inter-se transfer, etc.)	Acquisition pursuant to Voluntary Open Offer		
7.	Date of acquisition of/date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	March 10, 2014		

8.	Equity share capital/total voting capital of the TC before the said acquisition.	The issued and subscribed share capital of the TC is INR 847,030,170 (Indian Rupees Eight Hundred Forty Seven Million Thirty Thousand and Seventy only) consisting of 84,703,017 fully paid up equity shares
9.	Equity share capital/total voting capital of the TC after the said acquisition.	The issued and subscribed share capital of the TC is INR 847,030,170 (Indian Rupees Eight Hundred Forty Seven Million Thirty Thousand and Seventy only) consisting of 84,703,017 fully paid up equity shares
10.	Total diluted share/voting capital of the TC after the said acquisition.	The issued and subscribed share capital of the TC is INR 847,030,170 (Indian Rupees Eight Hundred Forty Seven Million Thirty Thousand and Seventy only) consisting of 84,703,017 fully paid up equity shares

Note:


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For GlaxoSmithKline Pte Ltd



Authorized Signatory

Place: Singapore
Date: 12 March 2014



भारतीय प्रतिभूति और विनियम बोर्ड **Securities and Exchange Board of India**

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) :			
	a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
	or			
	b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
	a) Shares	20609774	24.33	24.33
	b) Voting Rights (otherwise than by shares)	-	-	-
	c) Warrants,	-	-	-
	d) Convertible Securities	-	-	-
	d) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
	Total	20609774	24.33	24.33

भारतीय प्रतिभूति और विनियम बोर्ड **Securities and Exchange Board of India**

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	-

Signature of the Authorised Signatory

Place:

Singapore

Date:

2 April 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

6th April 2015

NATIONAL STOCK EXCHANGE,
EXCHANGE PLAZA, 5TH FLOOR,
PLOT No. C/1, G BLOCK,
BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI
400051

Dear Sir,

SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleon Investment Limited in respect of their shareholding in our Company as on 31st March 2015.

We hope the same is in order.

Thanking you,

Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
General Manager – Administration
& Company Secretary

Encl:

Corporate Identity Number
L24239MH1924PLC001161
Email id: askus@gsk.com
Web site address: www.gsk-india.com



भारतीय प्रतिभूति और विनियम बोर्ड Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) :			
	a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
	or			
	b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
	As of March 31st of the year, holding of:			
	a) Shares	3192238	3.77	3.77
	b) Voting Rights (otherwise than by shares)	-	-	-
	c) Warrants,	-	-	-
	d) Convertible Securities	-	-	-
	d) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
	Total	3192238	3.77	3.77



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	-

Signature of the Authorised Signatory

Place: Ebene, Mauritius

Date: 31 March 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

GSK
770 APR 2015
WORLD ADMINISTRATION

SEBI भारतीय प्रतिभूति और विनियम बोर्ड
Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s): Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
a) Shares		20609774	24.33	24.33
b) Voting Rights (otherwise than by shares)		-	-	-
c) Warrants,		-	-	-
d) Convertible Securities		-	-	-
d) Any other instrument that would entitle the holder to receive shares in the TC.		-	-	-
Total		20609774	24.33	24.33

SEBI भारतीय प्रतिभूति और विनियम बोर्ड
Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	-

Signature of the Authorised Signatory

Place: Singapore

Date: 3 April 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

6th April 2015

BOMBAY STOCK EXCHANGE LIMITED
PHIROZE JEEJEEBHAY TOWERS
DALAL STREET
MUMBAI
400001

Dear Sir,

SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleton Investment Limited in respect of their shareholding in our Company as on 31st March 2015.

We hope the same is in order.

Thanking you,

Sd/- Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni

Ajay Nadkarni
General Manager – Administration
& Company Secretary.

Encl:

Corporate Identity Number
L24239MH1924PLC001111

Email id: askus@gsk.com
Web site address: www.gsk-india.com



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange ; BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) :			
	a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
	or			
	b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
	a) Shares	3192238	3.77	3.77
	b) Voting Rights (otherwise than by shares)	-	-	-
	c) Warrants,	-	-	-
	d) Convertible Securities	-	-	-
	d) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
	Total	3192238	3.77	3.77

SEBI भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	-

Signature of the Authorised Signatory



Place: Ebene, Mauritius

Date: 31 March 2015

Note:


- 1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



भारतीय प्रतिभूति और विनियम बोर्ड Securities and Exchange Board of India



ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) :			
	a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
	or			
	b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
	a) Shares	20609774	24.33	24.33
	b) Voting Rights (otherwise than by shares)	-	-	-
	c) Warrants,	-	-	-
	d) Convertible Securities	-	-	-
	d) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
	Total	20609774	24.33	24.33



भारतीय प्रतिभूति और विनियम बोर्ड Securities and Exchange Board of India

Part-B**

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	

Signature of the Authorised Signatory

Place:

Singapore

Date:

3 April 2015

Note:

- 1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.


(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Pte - 2016 - to Company

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s):			
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
or			
b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	2,06,09,774	24.33	24.33
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	2,06,09,774	24.33	24.33



Signature of the Authorised Signatory

Place:

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Pte - 2016 - NSE

Rohan Mota

From: Ajay Nadkarni
Sent: Monday, April 04, 2016 5:24 PM
To: Rohan Mota
Subject: FW: Promoters Disclosure required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithkline Pharmaceuticals Limited

From: Paul Williamson
Sent: Monday, April 04, 2016 5:17 PM
To: takeover@nse.co.in
Cc: Ajay Nadkarni; Amita Patel
Subject: Promoters Disclosure required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithkline Pharmaceuticals Limited

Dear Sir,

Please find attached Promoters Disclosure(details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithkline Pharmaceuticals Limited

Sr no	Particulars	No of Shares	Percentage
1	Glaxo Group Limited	3,04,85,250	35.99
2	Eskaylab Limited	58,80,000	6.94
3	Burroghs Wellcome International Limited	33,60,000	3.97
4	GlaxoSmithKline Pte Ltd	2,06,09,774	24.33
5	Castleton Investment Limited	31,92,238	3.77
Total		6,35,27,262	75.00

Kindly take on record and confirm the same.

Regards

Paul Williamson
Corporate Secretariat

930 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
Email paul.y.williamson@gsk.com
Tel +442080474504

gsk.com | [Twitter](#) | [YouTube](#) | [Facebook](#) | [Flickr](#)




do more
feel better
live longer

This message is not intended for general use and may contain information which is sensitive, confidential or restricted. If you are not the authorised recipient, you are hereby notified that any use, copying, or distribution of this message, its contents or attachments is strictly prohibited

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s):			
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
or			
b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	2,06,09,774	24.33	24.33
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	2,06,09,774	24.33	24.33



Signature of the Authorised Signatory

Place:

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the T.C.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	3,192,238	3.77	3.77
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	3,192,238	3.77	3.77

Name of the Target Company



Signature of the Authorised Signatory

Place: Mauritius

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

2016

Rohan Mota

From: Ajay Nadkarni
Sent: Monday, April 04, 2016 2:02 PM
To: Anand Joshi; Rohan Mota
Subject: FW: Promoters Disclosure(details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited
Attachments: AADisclosures under Reg 30(1) 30(2) of SEBI Reg 2011 (2).pdf

FYI and file. Please confirm with BSE they have received this email.

Regards

Ajay

From: Paul Williamson
Sent: Friday, April 01, 2016 6:41 PM
To: corp.relations@bseindia.com
Cc: Ajay Nadkarni; Amita Patel
Subject: Promoters Disclosure(details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

Dear Sir,

Please find attached **Promoters Disclosure**(details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

Sr no	Particulars	No of Shares	Percentage
1	Glaxo Group Limited	3,04,85,250	35.99
2	Eskaylab Limited	58,80,000	6.94
3	Burroughs Wellcome International Limited	33,60,000	3.97
4	GlaxoSmithKline Pte Ltd	2,06,09,774	24.33
5	Castleton Investment Limited	31,92,238	3.77
Total		6,35,27,262	75.00

Kindly take on record and confirm the same.

Regards

Paul Williamson

Assistant Company Secretary – Group Operations
 Corporate Secretariat

GSK

980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom

Email paul.y.williamson@gsk.com


Tel +442080474504

gsk.com | [Twitter](#) | [YouTube](#) | [Facebook](#) | [Flickr](#)

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s):			
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or			
b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	2,06,09,774	24.33	24.33
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	2,06,09,774	24.33	24.33



Signature of the Authorised Signatory

Place:

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange , NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year 2016, holding of:			
a) Shares	3,192,238	3.77	3.77
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	3,192,238	3.77	3.77



Signature of the Authorised Signatory

Place: Mauritius

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.